Genedrive® MT-RNR1 ID Kit implemented at Dublin’s Rotunda Hospital
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that the Genedrive® MT-RNR1 ID Kit has been implemented at Dublin’s Rotunda Hospital Neonatal Intensive Care Unit (“NICU”). The Rotunda Hospital implementation is in addition to the 14 hospitals in the UK that are currently utilising the Genedrive® MT-RNR1 ID Kit under the PALOH-UK programme.
Funded initially by the Rotunda Foundation under the “Early Identification of Susceptibility to Gentamicin Induced Hearing Loss” programme, Rotunda Hospital admits approximately 1,400 babies each year into its NICU.
Further details are available at:
https://www.pressreader.com/ireland/irish-independent/20251101/281616721613956
Dr Gino Miele, CEO of genedrive plc, said: “Implementation at Rotunda Hospital is further validation of the product-market fit of our MT-RNR1 ID kit. Funded through a charitable foundation and led by Professor Brian Cleary, who has personal experience of hearing loss requiring a cochlear implant, we are excited to see the test being implemented internationally, in addition to those in PALOH-UK and the NHS England framework.”
Prof. Brian Cleary, Pharmacy Executive Manager, Rotunda Hospital, Dublin, said: “We are very excited to have access to point-of-care pharmacogenetic testing technology which enables us to identify babies at risk of significant hearing loss quickly and effectively. The ÉISTIGÍ project, supported by the Charlotte Stoker Fund, presents an exciting opportunity to assess the feasibility of point of care pharmacogenomics testing in this setting.”
Prof. Breda Hayes, Consultant Neonatologist, Rotunda Hospital, Dublin, said: “We are really happy with how the implementation is progressing. Bedside testing is a fantastic addition to the care that we provide, offering reassurance that we can reduce the risk of gentamicin-induced hearing loss in our most vulnerable patients.”
For further details please contact:
genedrive plc
+44 (0)161 989 0245
Gino Miele: CEO / Russ Shaw: CFO
